Extended Data Fig. 10: Oncogenic pathways in prostate cancer.
From: A genomic and epigenomic atlas of prostate cancer in Asian populations
a, Summary of genetic and epigenetic lesions in 12 curated pathways across the Chinese prostate cancer subtypes. b, Comparison of the frequency of disturbances in the AR pathway between CPGEA (primary), TCGA (primary) and SU2C (metastasis) cohorts. The frequency of coding mutations in each AR pathway gene is shown. c, The frequency of fusions, structural variations, noncoding mutations and epimutations in each AR pathway gene in the CPGEA cohort. Information on additional pathways is provided at http://www.cpgea.com. d, Comparison of pathway-level alterations across the CPGEA (206 samples, excluding 2 microsatellite instability (MSI) samples), TCGA (114 samples processed with the CPGEA pipeline), and SU2C cohorts (150 samples downloaded from cBioPortal). To compare across cohorts, only coding mutations and CNAs were considered. e, Frequency of coding alterations (CNAs, fusion genes and nonsynonymous coding mutations) noncoding alterations, and both for each pathway in the CPGEA cohort. f, Different levels of actionable mutations predicted by OncoKB in CPGEA and TCGA.
